Is Coherus BioSciences, Inc. overvalued or undervalued?

As of 6 May 2021, the valuation grade for Coherus BioSciences, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative valuation metrics, including a Price to Book Value of -0.52 and an EV to EBITDA of -3.01. Additionally, the company's Return on Capital Employed (ROCE) stands at a concerning -350.73%, further supporting the notion of overvaluation.
In comparison to peers, Coherus BioSciences has a significantly lower EV to EBITDA ratio of 0.2081 compared to SIGA Technologies, Inc., which boasts a ratio of 4.3137 and is rated attractive. Other risky peers like Nurix Therapeutics, Inc. show an EV to EBITDA of -1.2267, but still, Coherus's metrics are alarming. Despite a strong 1-month stock return of 42.99% compared to the S&P 500's 2.33%, the long-term performance is troubling, with a 5-year return of -92.31% versus the S&P 500's 96.61%. This stark contrast highlights the potential risks associated with investing in Coherus BioSciences.